

(19)



Europäisches Patentamt  
European Patent Office  
Office européen des brevets



(11)

EP 0 905 133 A1

(12)

## EUROPEAN PATENT APPLICATION

(43) Date of publication:  
31.03.1999 Bulletin 1999/13

(51) Int. Cl.<sup>6</sup>: C07D 401/04, A61K 31/47,  
C07D 401/14

(21) Application number: 98118064.9

(22) Date of filing: 23.09.1998

(84) Designated Contracting States:  
AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU  
MC NL PT SE  
Designated Extension States:  
AL LT LV MK RO SI

(30) Priority: 26.09.1997 JP 262356/97

(71) Applicant: KOWA CO. LTD.  
Nagoya-shi Aichi-ken 460 (JP)


(72) Inventors:  
• Timmerman, Hendrik  
2253 VM Voorschoten (NL)  
• Zang, Mingqiang  
Edinburgh EH20 9NE (Scotland) (GB)  
• Onogi, Kazuhiro  
Iruma-shi, Saitama (JP)

• Deushi, Takeo  
Sayama-shi, Saitama (JP)  
• Tamura, Masahiro  
Higashimurayama-shi, Tokyo (JP)  
• Tohma, Tsutomu  
Higashimurayama-shi, Tokyo (JP)  
• Wada, Yasushi  
Tachikawa-shi, Tokyo (JP)  
• Matsumoto, Jiro  
Sayama-shi, Saitama (JP)  
• Kanke, Toru  
Higashimurayama-shi, Tokyo (JP)

(74) Representative:  
Wächtershäuser, Günter, Prof. Dr. et al  
Wächtershäuser & Hartz,  
Patentanwälte,  
Tal 29  
80331 München (DE)

(54) Tetrazole derivatives as LTD4 and H1 antagonists

(57) The present invention is directed to a tetrazole derivative represented by the following formula (1) or a salt thereof:



wherein R<sup>1</sup> and R<sup>2</sup> independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group; R<sup>3</sup> represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; B represents a substituted or unsubstituted quinolyl group, a substituted or unsubstituted quinazolyl group, or a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond; and to a medicine containing the compound as an active ingredient. The medicine according to the present invention is endowed with excellent antileukotriene activity and anti-histaminic activity, and is useful for the prevention and treatment of, for example, asthma.

EP 0 905 133 A1

## Description

## BACKGROUND OF THE INVENTION

## 5 Field of the Invention

[0001] The present invention relates to a tetrazole derivative and salts thereof, which have excellent antileukotriene activity and antihistaminic activity and are useful as a medicine for a broad range of allergic diseases.

## 10 Background Art

[0002] Leukotrienes (LTs) participate in most inflammatory diseases, including asthma, psoriasis, rheumatism, and inflammatory colitis, and play an important role in inflammation caused by cytotoxic reactions.

[0003] Thus, on the basis of the finding that leukotrienes are predominant mediators in allergic reactions and inflammations, there have been discovered, in an attempt to relieve these pathological conditions, a number of substances that suppress the action or the synthesis of leukotrienes (S.T. Holgate *et al.*: J. Allergy Clin. Immunol. 98, 1-13 (1996)).

[0004] Leukotrienes are arachidonic acid metabolites synthesized by 5-lipoxygenase (5-LO) and are divided into two groups. One group refers to LTB<sub>4</sub> and exhibits strong chemotaxis towards leukocytes. The other group collectively encompasses cysteine leukotrienes (CysLTs), including LTC<sub>4</sub>, LTD<sub>4</sub>, and LTE<sub>4</sub>; these substances have long been called "slow-reacting substances of anaphylaxis (SRS-A)." In human tissues, CysLTs exert actions when they are coupled with their receptors. It has been found that a selective LTD<sub>4</sub> receptor inhibitor suppresses the contracting action of both LTC<sub>4</sub> and LTD<sub>4</sub> in human lung tissue, suggesting that the binding site of an LTD<sub>4</sub> receptor for LTD<sub>4</sub> also serves as a binding site for LTC<sub>4</sub> (Buckner C.K. *et al.*: Ann. NY Acad. Sci. 1988, 524; 181-6, Aharony D. *et al.*: New Trends in Lipid Mediators Research, Basel: Karger 1989; 67-71). LTE<sub>4</sub> is also considered to exert its action by the mediation of the same receptor available for LTD<sub>4</sub>. However, since its activity is low, LTE<sub>4</sub> is considered a partially active substance.

[0005] Meanwhile, histamine contracts bronchial smooth muscle and promotes capillary permeability when coupled to an H<sub>1</sub> receptor prevailing in the cell membrane, and thus is considered a significant mediator in allergic diseases. More specifically, histamine is considered to trigger aggravation of various symptoms of asthma due to its bronchial contracting action, and is also considered to increase leakage of blood components into intercellular space due to its capillary permeation promotion action, to thereby participate in the onset mechanism of allergic rhinitis and the formation of edema in conjunctivitis, etc. Antihistaminic agents have been used in the treatment of allergic diseases as mentioned above. However, conventional antihistaminic agents involve the fear of causing adverse side effects to the central nervous system, such as drowsiness, when such an agent is coupled to an H<sub>1</sub> receptor in the brain. In recent years, bronchial asthma has been considered a chronic airway inflammation in which eosinocytes participate. In this connection, attention has been drawn to a delayed response which manifests airway constriction unique to asthma, as a result of infiltration of inflammation cells into bronchial mucosa and hypersecretion from the mucosa.

[0006] Briefly, in allergic diseases such as asthma, pathological profiles of immediate asthma response—i.e., bronchoconstriction and formation of edema in which histamine and similar mediators participate—and those of late asthma response—i.e., airway constriction that results from cellular infiltration, mucous secretion, hyperplasia of membrane, etc. in which leukotrienes participate—are deemed to play a significant role in the manifestation of pathological conditions. Similarly, the pathological profile of allergic rhinitis also comes to be elucidated as a two-phase reaction including an immediate asthma response phase manifesting ptarmus and hypersecretion of pituita, and a late asthma response phase manifesting nasal congestion due to swelling of the nasal membrane; wherein histamine participates in the former and leukotriene participates in the latter.

[0007] Accordingly, it is considered that a compound which exhibits antagonism against both a histamine H<sub>1</sub> receptor and an LTD<sub>4</sub> receptor and which minimally migrates into the brain can serve as a medicine having reduced side effects and can be effective for the prevention and treatment of a variety of symptoms from the instant response phase to the delayed response phase of a broad range of allergic diseases; in particular, asthma and rhinitis.

[0008] However, until realization of the present invention, a compound exhibiting sufficient antagonism against both the LTD<sub>4</sub> receptor—which relates to the late asthma response phase—and the histamine H<sub>1</sub> receptor—which relates to the immediate asthma response phase—had not yet been found. Moreover, many LTD<sub>4</sub> antagonists which are now being developed have at least one acid group in the molecule and are hydrophilic compounds having high polarity; inevitably they are not sufficiently absorbed by the oral route, leading to an increase in dose of these types of drugs and causing side effects.

55


## SUMMARY OF THE INVENTION

[0009] In view of the foregoing, the present inventors have conducted extensive studies in search of a compound

which has both anti-leukotriene activity and antihistaminic activity and which does not have the aforementioned drawbacks, and have found that the compound represented by the following formula (1) satisfactorily meets the present purposes, to thereby complete the present invention.

[0010] Accordingly, an object of the present invention is to provide a novel compound which has antihistaminic activity and anti-leukotriene activity, which minimally migrates into the brain, and which has no acid group in the molecule.

[0011] In one aspect of the present invention, there is provided a tetrazole derivative or a salt thereof represented by the following formula (1):



wherein  $R^1$  and  $R^2$  independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group;  $R^3$  represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; B represents a substituted or unsubstituted quinolyl group, a substituted or unsubstituted quinazolyl group, or a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond.

[0012] In another aspect of the present invention, there is provided a medicine comprising as an active ingredient a tetrazole derivative represented by the above-described formula (1) or a salt thereof.

[0013] In still another aspect of the present invention, there is provided a pharmaceutical composition comprising a tetrazole derivative represented by the above-described formula (1) or a salt thereof, and a pharmacologically acceptable carrier.

[0014] In yet another aspect of the present invention, there is provided use, as a medicine, of a tetrazole derivative represented by the above-described formula (1) or a salt thereof.

[0015] In yet another aspect of the present invention, there is provided a method for the treatment of allergic diseases, which method comprises administering to a patient in need thereof an effective amount of a tetrazole derivative represented by the above-described formula (1) or a salt thereof.

[0016] In yet another object of the present invention, there is provided a method for the treatment of a disease selected from the group consisting of asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, psoriasis, rheumatism, inflammatory colitis, cerebral ischemia, and cerebral apoplexy, which method comprises administering to a patient in need thereof an effective amount of a tetrazole derivative represented by the above-described formula (1) or a salt thereof.

#### BEST MODE FOR CARRYING OUT THE INVENTION

[0017] In the tetrazole derivative of formula (1), the lower alkyl groups represented by  $R^1$  or  $R^2$  include C1-C6 linear or branched alkyl groups. Specific examples thereof include a methyl group, an ethyl group, a n-propyl group, an i-propyl group, a n-butyl group, an i-butyl group, a sec-butyl group, a t-butyl group, a pentyl group, and a hexyl group. Of these groups, a methyl group and a t-butyl group are particularly preferred. The alkoxy group may be linear or branched and may have 1-6 carbon atoms. Examples of preferred alkoxy groups include a methoxy group, an ethoxy group, a n-propoxy group, an i-propoxy group, a butoxy group, a pentyloxy group, and a hexyloxy group. Of these, a methoxy group, an ethoxy group and a n-propoxy group are particularly preferred. The alkoxy groups may have substituents. Examples of the substituents include an alkoxy group; a halogen atom; a phenyl group which may have a substituent such as a quinolyl methoxy group; a piperazinyl group which may have a substituent such as a methyl group or a quinolyl(methyl) group; and a di-(C1-C4)alkylamino group such as a dimethylamino group or a diethylamino group. The alkanoyloxy group preferably has 2 to 5 carbon atoms; for example, mention may be given of an acetyloxy group, a propionyloxy group, and an n-butyloxy group. The alkanoyloxy group may have a substituent such as an amino group.

[0018] In the formula, the lower alkyl groups represented by  $R^3$  include C1-C6 linear or branched alkyl groups. Specific examples thereof include a methyl group, an ethyl group, a n-propyl group, an i-propyl group, a n-butyl group, an i-butyl group, a sec-butyl group, a t-butyl group, a pentyl group, and a hexyl group. Of these groups, a methyl group is particularly preferred. The lower alkyl groups may have substituents. Examples of the substituents include a halogen atom, an amino group, a phenyl group, and a heterocyclic group such as a piperazinyl group. These substituents may

further have substituents such as a C1-C4 alkyl group, e.g., methyl or ethyl; a quinolyl C1-C4 alkoxy group, e.g., a quinolyl methoxy group; a benzimidazolyl C1-C4 alkoxy group, e.g., a benzimidazolyl methoxy group; or a quinolyl C1-C4 alkyl group, e.g., a quinolyl methyl group. Preferably, R<sup>3</sup> is a hydrogen atom, a methyl group, a dimethylaminomethyl group, or a 3-[4-(2-quinolylmethyl)piperazinyl]propyl group.

5 [0019] Examples of groups represented by B include a quinolyl group, a quinazolyl group, and a benzimidazolyl group; these groups may have substituents. Examples of the substituents include a C1-C4 alkyl group, e.g., a methyl group or an ethyl group; and a (C1-C4)alkoxy(C1-C4)alkyl group, e.g., an ethoxyethyl group or a methoxymethyl group.


[0020] No particular limitation is imposed on the salts of the compounds of the present invention represented by formula (1), so long as they are pharmacologically acceptable. Examples of such salts include acid addition salts of mineral acids, such as hydrochlorides, hydrobromides, hydroiodides, sulfates, and phosphates; and acid addition salts of organic acids, such as benzoates, methanesulfonates, ethanesulfonates, benzenesulfonates, p-toluenesulfonates, oxalates, maleates, fumarates, tartarates and citrates.

[0021] The compound of formula (1) of the present invention (hereinafter may be referred to as compound (1)) may take the form of a solvate such as a hydrate, and the present invention encompasses such a solvate.

15 [0022] Also, the compound (1) may take the form of a ketoenol tautomer, and the present invention encompasses such a tautomer.

[0023] The compound (1) of the present invention may be prepared by, for example, the methods described below.


## Method A



wherein X represents a halogen atom, and  $R^1$ ,  $R^2$ , A, and B have the same meanings as described above.


[0024] Briefly, the compound (1a) of the present invention in which  $R^1$  and  $R^2$  independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, or a lower alkoxy group may be prepared, as shown in Method A, by causing a reaction between a tetrazolylquinolinone compound (2) and a halogen compound (3) in an amount of one equivalent, in the presence of an excessive amount of a base such as sodium carbonate or potassium carbonate, in an aprotic polar solvent such as dimethylformamide (DMF), dimethylsulfoxide (DMSO), or hexamethylphosphoramide (HMPA) within a temperature range of 0°C to a reflux temperature (preferably from room temperature to 80°C) for 1-7 days. In the case in which neither  $R^1$  nor  $R^2$  is a hydroxyl group, a compound (1a') of the present invention wherein  $R^3$  is a B-A-benzyl group may be by-produced, whereas in the case in which  $R^1$  and/or  $R^2$  is a hydroxyl group, there may be by-produced a compound (1a'') of the present invention wherein the hydrogen of the hydroxyl group has been substituted by a B-A-benzyl group. For this reason, in order to obtain a compound (1) of the present invention in which  $R^1$  and/or  $R^2$  is a hydroxyl group, the hydroxyl group of the compound (2) is protected by use of an appropriate protective group, followed by removal of the protection (Method B).

Method C.D



wherein  $R^1$ ,  $R^2$ , A, B, and X have the same meanings as described above,  $R^4$  represents a lower alkyl group which may have a substituent,  $R^5$  represents a lower alkyl group which may have a substituent, and m is an number between 1 and 4 inclusive.

[0025] Alkylation of the compound (1a) transforms the compound (1a) into a compound (1c) of the present invention in which  $R^3$  is a substituted or unsubstituted lower alkyl group ( $R^4$ ) (Method C). Alternatively, haloalkylation transforms the compound (1a) into a compound (1d), which may further be piperazinylated to a compound (1d') of the present invention (Method D).




wherein  $R^1$ ,  $R^3$ , A, B, X, and m have the same meanings as defined above,  $R^6$  represents a dialkylaminoalkyl group,  $R^7$  represents a lower alkyl group, and  $R^8$  represents an alkyl group.

[0026] The compound (1e) of the present invention in which  $R^2$  is a dialkylaminoalkoxy group is obtained through diaminoalkylation of the compound (1b) in which  $R^2$  is a hydroxyl group (Method E). Also, the compound (1f') of the present invention in which  $R^2$  is a piperazinylalkoxy group is obtained by haloalkylation of compound (1b) and by subsequent piperazinylolation of the resultant compound (1f) (Method F). The compound (1g) of the present invention in which  $R^2$  is an alkylcarbonyloxy group is obtained through esterification of the hydroxyl group of compound (1b)

(Method G).

[0027] Independently, the aforementioned compound (2), which serves as a raw material of the compound (1) of the present invention may be formed as follows. Briefly, a cyanoquinoline compound (4) is first formed according to a known method, e.g., a method described by Bhaduri, Amiya Prasad *et al.*; J. Heterocyclic Chem., 23, 409-411, 1985, then the cyanoquinoline compound (4) is reacted with an azide compound such as sodium azide, in an aprotic polar solvent such as DMF, DMSO, or HMPA, in the presence of ammonium chloride, at a temperature between 0°C and 200°C inclusive, preferably between room temperature to 120°C inclusive, for several hours to one day.

#### Method H



wherein R<sup>1</sup> and R<sup>2</sup> have the same meanings as defined above.


[0028] Among several compounds of formula (3) which serve as another raw materials, the halogen compounds of formulas (3a) to (3c) may be prepared, for example, by the following processes.

[0029] The halogen compound (3a) may be commercially obtained, or may be prepared in accordance with a method described, for example, by Musser, John H. *et al.*; J. Med. Chem. 33(1), 240-245, 1990 or by Iemura, Ryuichi *et al.*; J. Heterocyclic Chem. 24(1), 31-37, 1987.



[0030] The halogen compounds (3b) and (3c) may be prepared, for example, by the following method.



Method I



Method J



wherein  $R^9$  represents an alkyl group or a C1-C4 alkoxy C1-C4 alkyl group, and X represents a halogen atom.

[0031] When the halogen compound (3a) and hydroxybenzyl alcohol in an equivalent amount are allowed to react with each other in an aprotic polar solvent such as DMF, DMSO, or HMPA, in the presence of an excessive amount of amount of a base such as sodium carbonate or potassium carbonate, at a temperature between 0°C and a reflux tem-

perature inclusive, preferably between room temperature to 60°C inclusive, for one to 7 days, there is obtained a benzyl alcohol (5a).

[0032] Independently, a benzyl alcohol of formula (5b) may be prepared as follows. The halogen (3a), together with an equivalent amount of  $\text{PPh}_3$  (Ph stands for phenyl), is first refluxed in an inert solvent such as benzene, toluene, or xylene for 12-48 hours, to thereby synthesize a corresponding phosphonium salt. The phosphonium salt is allowed to react with an equimolar amount of  $t\text{-BuOK}$  (potassium tert-butoxide) in an absolute THF under nitrogen or argon, to thereby prepare a Wittig reagent. To the Wittig reagent are added equimolar amounts of phthalic aldehyde, isophthalic aldehyde, and terephthalic aldehyde, and the mixture is subjected to refluxing for 1 to 12 hours, to thereby obtain an aldehyde compound (6). The aldehyde compound (6) is then reacted with sodium borohalide in a protic polar solvent such as methanol or ethanol at a temperature between 0°C and a reflux temperature inclusive, preferably at room temperature, for 1-24 hours, to thereby obtain the benzyl alcohol (5b).

[0033] The thus-obtained benzyl alcohol (5a) or (5b) is allowed to react with an excessive amount of thionyl chloride in an inert solvent such as THF, Chloroform, or methylene chloride, at a temperature between 0°C and a reflux temperature inclusive, preferably at room temperature, for 1-24 hours, to thereby obtain a halogen compound (3b) or (3c).

[0034] After completion of the above-described sequence of reactions, a suitable treatment of the obtained compound according to a customary method provides a target compound (1) of the present invention, which may further be purified by a customary purification means such as recrystallization, column chromatography, etc., as desired. If necessary, the compound may be converted into any one of the aforementioned salts.

[0035] The thus-obtained compounds (1) and their salts of the present invention exhibit excellent anti-leukotriene activity and excellent antihistaminic activity, as demonstrated by the below-described examples, and are useful as remedies, including preventive drugs and therapeutic drugs, for asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, psoriasis, rheumatism, inflammatory colitis, cerebral ischemia, and cerebral apoplexy.

[0036] The medicine of the present invention comprises as an active ingredient the above-described compound (1), a salt thereof, or a hydrate of the compound (1) or the salt. Examples of the manner of administration of the present medicine include oral administrations by way of tablets, capsules, granules, powders, and syrups and non-oral administrations such as intravenous injections, intramuscular injections, suppositories, inhalations, percutaneous absorptions, eye drops, and nasal drops. In order to prepare pharmaceutical preparations of a variety of forms, the aforementioned active ingredient may be used alone or in combination with a pharmaceutical vehicle, such as, for example, an excipient, a binder, a bulking agent, a disintegrant, a surfactant, a lubricant, a dispersing agent, a buffering agent, a preservative, a flavoring agent, a perfume, a coating agent carrier, a diluent, etc.

[0037] The dosage of the medicine of the present invention varies in accordance with the age, body weight, symptom, manner of administration, frequency of the administration, etc. In general, in the case of adults, it is preferred that the compound of the present invention be administered in an amount of 1-1,000 mg per day at a time or as divided in several times, orally or non-orally.

## EXAMPLES

[0038] The present invention will next be described by way of examples, which should not be construed as limiting the invention thereto.

### Production Example 1

Synthesis of 6-methoxy-3-tetrazolyl-1,2-dihydroquinolin-2-one sodium salt:

[0039] 3-Cyano-6-methoxy-1,2-dihydroquinolin-2-one (78.6 g, 393 mmol) was dissolved in DMF (1 liter), and ammonium chloride (83.8 g, 1.57 mol) and sodium azide (102.2 g, 1.57 mol) were added to the resultant mixture. The mixture was stirred for 12 hours at a bath temperature of 120°C. The reaction mixture was concentrated under reduced pressure. Subsequently, an 2N sodium hydroxide aqueous solution (800 ml) was added to the reaction mixture, and the mixture was heated. After removal of the insoluble matter by filtration, the filtrate was allowed to cool. The crystals that precipitated were collected, to thereby obtain the title compound as pale yellow needles (90.0 g, 339 mmol, 86.3%).

mp: >260°C

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  (ppm): 11.9(1H, br), 8.45(1H, s), 7.34(1H, d,  $J=1.5\text{Hz}$ ), 7.30(1H, d,  $J=8.8\text{Hz}$ ), 7.15(1H, dd,  $J=8.8, 1.5\text{Hz}$ ), 3.80(3H, s).

IR (KBr)  $\text{cm}^{-1}$ : 3445, 1665, 1624, 1510, 1461, 1368, 1234, 1171, 1034, 638.

## Production Example 2

## Synthesis of 6-tert-Butyl-3-tetrazolyl-1,2-dihydroquinolin-2-one:

- 5 [0040] 6-tert-Butyl-3-cyano-1,2-dihydroquinolin-2-one (1.74 g, 7.7 mmol) was dissolved in DMF (20 ml), and ammonium chloride (1.65 g, 30.8 mol) and sodium azide (2.00 g, 30.8 mol) were added to the resultant mixture. The mixture was stirred at a bath temperature of 120°C for 16 hours. Water was added to the reaction mixture. After removal of the precipitates by filtration, the reaction mixture was recrystallized from DMF-methanol. The crystals that precipitated were collected, to thereby obtain the title compound as yellow powder (1.08 g, 4.0 mmol, 52%).

10 mp : 280-286°C (d.)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 8.96(1H, s), 7.95(1H, d, J=2.2Hz), 7.75(1H, dd, J=8.5, 2.2Hz), 7.39(1H, d, J=8.5Hz), 1.34(9H, s).

IR (KBr) cm<sup>-1</sup> : 2964, 1667, 1625, 1535, 1473, 1365, 1261, 1156, 1036, 626

## Production Examples 3 through 7

[0041] In a manner similar to that of Production Examples 1 and 2, the following compounds were obtained.

Table 1

Ex.	Compound	Property	m.p.
3	7-Hydroxy-3-tetrazolyl-1,2-dihydroquinolin-2-one	Brown powder	>280°C
4	8-Hydroxy-3-tetrazolyl-1,2-dihydroquinolin-2-one	Brown powder	>280°C
5	Sodium 6-methoxymethoxy-3-tetrazolyl-1,2-dihydroquinolin-2-one	Pale yellow scales	>270°C
6	3-Tetrazolyl-1,2-dihydroquinolin-2-one	Pale yellow powder	>280°C
7	5-Ethoxy-8-methyl-3-tetrazolyl-1,2-dihydroquinolin-2-one	Yellow powder	278-280°C (d.)

## Production Example 8

## Synthesis of 3-(2-quinolylmethoxy)benzyl chloride:

[0042] To a solution of 3-(2-quinolylmethoxy)benzyl alcohol (3.58 g, 13.5 mmol) in CHCl<sub>3</sub> (100 ml) was added SOCl<sub>2</sub> (2 ml). The mixture was stirred at room temperature for 24 hours. A small amount of methanol was added to the reaction mixture, and the solvent thereof was removed under reduced pressure, to thereby obtain the title compound as white powder.

## Production Example 9

Synthesis of 2-(2-quinazolylmethoxy)benzyl alcohol: To a solution of 2-Chloromethylquinazoline (5.00 g,

- 45 [0043] 28 mmol) in DMF (50 ml) were added potassium carbonate (4.26 g, 31 mmol) and tetra-n-butylammoniumbromide (903 mg, 2.8 mmol). 3-Hydroxybenzylalcohol (3.48 g, 28 mmol) was added to the resultant mixture, and the mixture was stirred at room temperature for five days. Subsequently, the reaction mixture was concentrated under reduced pressure. Chloroform and water were added to the resultant mixture, and the organic phase was extracted from the mixture. The organic phase was dried over sodium sulfate anhydrate, concentrated under reduced pressure, and recrystallized from a chloroform-n-hexane mixture, to thereby obtain the title compound as pale yellow powder (6.94 g, yield: 93.1%).

mp : 92-96°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 9.43(1H, s, -C<sub>8</sub>H<sub>5</sub>N<sub>2</sub>-), 8.07(1H, d, J=9.0Hz, -C<sub>8</sub>H<sub>5</sub>N<sub>2</sub>-), 7.95(1H, d, J=7.5Hz, -C<sub>8</sub>H<sub>5</sub>N<sub>2</sub>-), 7.93(1H, d, J=9.0Hz, -C<sub>8</sub>H<sub>5</sub>N<sub>2</sub>-), 7.67(1H, dd, J=7.5, 7.5Hz, -C<sub>8</sub>H<sub>5</sub>N<sub>2</sub>-), 7.25(1H, dd, J=7.8, 7.8Hz, -C<sub>6</sub>H<sub>4</sub>-), 7.11(1H, s, -C<sub>6</sub>H<sub>4</sub>-), 6.99(1H, d, J=7.8Hz, -C<sub>6</sub>H<sub>4</sub>-), 6.96(1H, d, J=7.8Hz, -C<sub>6</sub>H<sub>4</sub>-), 5.46(2H, s, C<sub>8</sub>H<sub>5</sub>N<sub>2</sub>-CH<sub>2</sub>-), 4.65(2H, s, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-OH).

IR (KBr) cm<sup>-1</sup> : 3328, 1621, 1613, 1582, 1441, 1378, 1292, 1077, 752.

## Production Example 10

Synthesis of 3-(N-methylbenzimidazol-2-ylmethoxy)-benzyl alcohol:

- 5 [0044] In a manner similar to that of Production Example 9, the title compound was obtained as pale yellow needles by use of 2-chloromethyl-N-methylbenzimidazole (yield: 58.4%).

mp : 183-185°C

- 10 <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 7.69(1H, m, C<sub>8</sub>H<sub>7</sub>N<sub>2</sub>-), 7.16-7.32(4H, m, Ar-H), 7.02(1H, s, -C<sub>6</sub>H<sub>4</sub>-), 6.88-6.94(2H, m, -C<sub>6</sub>H<sub>4</sub>-), 5.29(2H, s, C<sub>8</sub>H<sub>7</sub>N<sub>2</sub>-CH<sub>2</sub>-), 4.61(2H, s, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-OH), 3.81(3H, s, N-CH<sub>3</sub>).  
IR (KBr) cm<sup>-1</sup> : 2850, 1594, 1482, 1441, 1366, 1259, 1227, 1048, 1029, 750.

## Production Example 11

- 15 Synthesis of 4-(2-N-methylbenzimidazol-2-ylmethoxy)benzyl alcohol:

[0045] In a manner similar to that of Production Example 9, the title compound (yield: 46.7%) was obtained as pale yellow prisms by use of 2-Chloromethyl-N-methylbenzimidazole and 4-Hydroxybenzyl alcohol.

mp : 176-180°C

- 20 <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 7.78(1H, m, C<sub>8</sub>H<sub>7</sub>N<sub>2</sub>-), 7.23-7.38(3H, m, C<sub>8</sub>H<sub>7</sub>N<sub>2</sub>-) 7.30(2H, d, J=8.6Hz, -C<sub>6</sub>H<sub>4</sub>-), 7.04(2H, d, J=8.6Hz, -C<sub>6</sub>H<sub>4</sub>-), 5.34(2H, s, C<sub>8</sub>H<sub>7</sub>N<sub>2</sub>-CH<sub>2</sub>-), 4.62(2H, s, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-OH), 3.88(3H, s, N-CH<sub>3</sub>).  
IR (KBr) cm<sup>-1</sup> : 3174, 2846, 1607, 1585, 1507, 1484, 1240, 1047, 1030, 734.

## Production Example 12

Synthesis of 3-[N-(2-ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl alcohol:

- 30 [0046] In a manner similar to that of Production Example 9, the title compound (yield: 90.3%) was obtained as colorless needles by use of 2-Chloromethyl-N-(2-ethoxyethyl)benzimidazole.

mp : 105-107°C

- 35 <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 7.71(1H, m, Ar-H), 7.41(1H, m, Ar-H), 7.23-7.34(3H, m, Ar-H), 7.11(1H, s, -C<sub>6</sub>H<sub>4</sub>-), 6.96-7.62(2H, m, -C<sub>6</sub>H<sub>4</sub>-), 5.43(2H, s, C<sub>11</sub>H<sub>13</sub>N<sub>2</sub>O-CH<sub>2</sub>O-), 4.68(2H, d, J=5.6Hz, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>OH), 4.48(2H, t, J=5.4Hz, -CH<sub>2</sub>-CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>), 3.74(2H, t, J=5.4Hz, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>), 3.39(2H, q, J=6.8Hz, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>), 2.24(1H, br, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>OH), 1.10(3H, t, J=6.8Hz, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>).  
IR (KBr) cm<sup>-1</sup> : 2875, 1594, 1471, 1445, 1426, 1369, 1258, 1154, 1050, 1035, 761.

## Production Example 13

Synthesis of 4-[N-(2-ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl alcohol:

[0047] In a manner similar to that of Production Example 9, the title compound (yield: 83.4%) was obtained as pale yellow prisms by use of 2-chloromethyl-N-(2-ethoxyethyl)benzimidazole and 4-Hydroxybenzyl alcohol.

mp : 90-92°C

- 45 <sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 7.78(1H, m, Ar-H), 7.41(1H, m, Ar-H), 7.25-7.34(4H, m, Ar-H), 7.08(2H, d, J=8.8Hz, -C<sub>6</sub>H<sub>4</sub>-), 5.44(2H, s, C<sub>11</sub>H<sub>13</sub>N<sub>2</sub>O-CH<sub>2</sub>O-), 4.62(2H, d, J=5.7Hz, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>-OH), 4.49(2H, t, J=5.6Hz, -CH<sub>2</sub>-CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>), 3.75(2H, t, J=5.6Hz, -CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>), 3.39(2H, q, J=7.1Hz, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>), 1.66(1H, t, J=5.7Hz, -C<sub>6</sub>H<sub>4</sub>-CH<sub>2</sub>OH), 1.10(3H, t, J=7.1Hz, CH<sub>2</sub>CH<sub>2</sub>OCH<sub>2</sub>CH<sub>3</sub>).  
50 IR (KBr) cm<sup>-1</sup> : 3180, 2858, 1609, 1587, 1509, 1472, 1417, 1237, 1117, 1036, 747.

## Production Example 14

- 55 Synthesis of 3-[2-(2-quinoly)ethenyl]benzyl alcohol:

[0048] 3-[2-(2-quinoly)ethenyl]benzyl aldehyde (25.92 g, 0.1 mol) was dissolved in methanol (300 ml). Sodium borohydride (7.57 g, 0.2 mol) was added to the resultant mixture, and the mixture was stirred at room temperature for one

hour. The solvent of the reaction mixture was removed under reduced pressure. Water was added to the obtained residue, and the organic phase was extracted from the solution with ethyl acetate. The organic phase was dried over magnesium sulfate anhydrate, and recrystallized from ethyl acetate, to thereby obtain the title compound as pale yellow powder (21.42 g, 82.0 mmol, 82.0%).

#### Production Examples 15 through 22

[0049] In a manner similar to that of Production Example 8, the following compounds were obtained.

Table 2

Ex.	Compound	Property
15	4-(2-Quinolylmethoxy)benzyl chloride	White powder
16	3-(2-Quinazolylmethoxy)benzyl chloride	White powder
17	4-(2-Quinazolylmethoxy)benzyl chloride	White powder
18	3-(2-N-Methylbenzimidazol-2-ylmethoxy)benzyl chloride	White powder
19	4-(2-N-Methylbenzimidazol-2-ylmethoxy)benzyl chloride	White powder
20	3-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl chloride	Pale yellow oily material
21	4-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl chloride	Pale yellow oily material
22	3-[2-(2-Quinolyl)ethenyl]benzyl chloride	White powder

#### Examples 1 and 2

Synthesis of 6-methoxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one and 6-methoxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one:

[0050] To 6-methoxy-3-tetrazolyl-1,2-dihydroquinolin-2-one sodium salt (36.7 g 138 mmol), sodium carbonate (14.7 g, 138 mmol), and tetra-n-butylammoniumbromide (22.3 g, 69.1 mmol), was added DMF (2 liters). (2-Quinolylmethoxy)benzyl chloride (58.7 g) was added to the resultant mixture, and the mixture was stirred for 15 hours at a bath temperature of 80°C. Subsequently, the solvent of the reaction mixture was removed under reduced pressure. To the obtained residue was added an 2N sodium hydroxide aqueous solution (1 liter). The organic phase was extracted from the solution with a mixture of chloroform-methanol (5:1). The organic phase was dried over sodium sulfate anhydrate, recrystallized from ethyl acetate, subjected to silica gel column chromatography (chloroform-methanol (5:1)), and concentrated under reduced pressure. The obtained residue was recrystallized from a chloroform-methanol-ether mixture, to thereby obtain crude 6-methoxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one as first-deposited crystals, and crude 6-methoxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one as second-deposited crystals.

[0051] The first-deposited crystals were further purified through recrystallization (with DMF-ether), to thereby obtain 6-methoxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one (24.0 g, yield: 35.4%) as yellow powder.

mp : 213-214°C (d.)

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm) : 12.01(1H, br), 8.56(1H, s), 8.39(1H, d, J=8.3Hz), 8.00(1H, d, J=7.8Hz), 8.03-7.94(2H, m), 7.76(1H, ddd, J=8.3, 6.8, 1.5Hz), 7.67(1H, d, J=8.3Hz), 7.59(1H, m), 7.41(1H, d, J=2.5Hz), 7.35(1H, dd, J=7.8, 7.8Hz), 7.31(1H, d, J=8.8Hz), 7.25(1H, dd, J=8.8, 2.5Hz), 7.15-7.06(2H, m), 6.98 (1H, d, J=7.8Hz), 5.99(2H, s), 5.37(2H, s), 3.80(3H, s).

IR (KBr) cm<sup>-1</sup> : 3432, 1676, 1629, 1587, 1497, 1378, 1285, 1239, 1165, 1030, 829, 598.

[0052] Also, the second-deposited crystals were further purified through recrystallization (with DMF-ether), to thereby obtain 6-methoxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one (12.1 g, yield: 19.0%) as pale yellow powder.

mp : 215-217°C (d.)

<sup>1</sup>H-NMR (DMSO-d<sub>6</sub>) δ (ppm) : 12.39(1H, br), 8.35(1H, d, J=8.8Hz), 8.31(1H, s), 8.00(1H, d, J=7.8Hz), 7.98(1H, d, J=7.3Hz), 7.78(1H, ddd, J=8.3, 6.8, 1.5Hz), 7.62(1H, dd, J=7.8, 7.3Hz), 7.55(1H, d, J=8.3Hz), 7.38(1H, d,

J=8.8Hz), 7.34-7.27(2H m), 7.20(1H, m), 6.97-6.90(2H, m), 6.77(1H, d, J=7.8Hz), 5.73(2H, s), 5.23(2H, s), 3.78(3H, s).

IR (KBr)  $\text{cm}^{-1}$ : 3434, 1665, 1625, 1498, 1453, 1380, 1264, 1244, 1171, 1034, 827.

5 Examples 3 through 34

[0053] In a manner similar to that of Examples 1 and 2, the compounds shown in Tables 3 and 4 below were obtained.

10 Table 3

Ex.	Compound	m.p.
3	3-{2-[3-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl]tetrazolyl}-6-hydroxyquinolin-2-one	200~202°C (d.)
4	3-{2-[4-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl]tetrazolyl}-6-hydroxyquinolin-2-one	240~242°C (d.)
5	3-{1-[4-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl]tetrazolyl}-6-hydroxyquinolin-2-one	245~248°C (d.)
6	3-{2-[4-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl]tetrazolyl}-6-methoxyquinolin-2-one	200~202°C
7	3-{1-[4-[N-(2-Ethoxyethyl)benzimidazol-2-ylmethoxy]benzyl]tetrazolyl}-6-methoxyquinolin-2-one	234~236°C (d.)
8	3-{2-[3-(N-Methylbenzimidazol-2-ylmethoxy)benzyl]tetrazolyl}quinolin-2-one	262~265°C (d.)
9	3-{1-[3-(N-Methylbenzimidazol-2-ylmethoxy)benzyl]tetrazolyl}quinolin-2-one	234~236°C (d.)
10	6-Methoxy-3-{2-[3-(2-quinazolylmethoxy)-benzyl]tetrazolyl}quinolin-2-one	186~189°C
11	6-Methoxy-3-{2-[4-(2-quinazolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	197~199°C (d.)
12	6-Methoxy-3-{1-[4-(2-quinazolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	197~199°C (d.)
13	6-Methoxy-3-{2-[3-(2-quinolyl)ethenyl]benzyl]tetrazolyl}quinolin-2-one	241~244°C (d.)
14	6-Methoxy-3-{1-[3-(2-quinolyl)ethenyl]benzyl]tetrazolyl}quinolin-2-one	250~252°C (d.)
15	5-Ethoxy-8-methyl-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	221~223°C
16	5-Ethoxy-8-methyl-3-{2-[4-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	150~154°C (d.)
17	6-tert-Butyl-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	102~105°C
18	6-tert-Butyl-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	105~107°C

45 Table 4

Ex.	Compound	m.p.
19	6-tert-Butyl-3-{1-[4-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	216~219°C
20	7-Hydroxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	262~264°C (d.)
21	8-Hydroxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	262~264°C (d.)
22	6-Hydroxy-3-{2-[4-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	231~234°C (d.)
23	6-Hydroxy-3-{1-[4-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	250~252°C (d.)
24	6-Methoxy-3-{2-[4-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	206~210°C (d.)
25	6-Methoxy-3-{1-[4-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	206~209°C (d.)
26	3-{2-[3-(2-Quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	226~229°C (d.)

Table 4 (continued)

Ex.	Compound	m.p.
27	3-[1-[3-(2-Quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	238~241°C (d.)
28	6-Hydroxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	260~267°C (d.)
29	6-Hydroxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	272~275°C (d.)
30	6-[3-(2-Quinolylmethoxy)benzyl]oxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	195~199°C (d.)
31	1-[3-(2-Quinolylmethoxy)benzyl]-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	114~116°C
32	6-Hydroxy-1-[3-(2-quinolylmethoxy)benzyl]-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	175~178°C (d.)
33	6-tert-Butyl-1-[3-(2-quinolylmethoxy)benzyl]-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	96~99°C
34	6-Methoxy-1-[4-(N-methylbenzimidazole-2-ylmethoxy)benzyl]-3-[2-[4-N-methylbenzimidazol-2-ylmethoxy)benzyl]tetrazolyl]quinolin-2-one	217~219°C

## Examples 35 and 36

Synthesis of 6-methoxymethoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one and 6-methoxymethoxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one:

[0054] In a manner similar to that of Examples 1 and 2, the title compounds were obtained.

[0055] The data of 6-methoxymethoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one are as follows:

mp : 197-200°C (d.)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 11.24(1H, br), 8.63(1H, s), 8.18(1H, d, J=8.3Hz), 8.09(1H, d, J=8.5Hz), 7.72(1H, ddd, J=8.5, 7.1, 1.5Hz), 7.64(1H, d, J=8.5Hz), 7.52(1H, ddd, J=8.1, 6.8, 1.2Hz), 7.35-7.24(4H, m), 7.13(1H, m), 7.10-6.99(2H, m), 5.87 (2H, s), 5.39(2H, s), 5.20(2H, s), 3.50(3H, s).

IR (KBr) cm<sup>-1</sup> : 1667, 1623, 1588, 1510, 1493, 1443, 1428, 1289, 1230, 1155, 1074, 996, 825, 529.

[0056] The data of 6-methoxymethoxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one are as follows:

mp : 202-206°C (d.)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 11.60(1H, br), 8.13(1H, s), 8.12(1H, d, J=8.8Hz), 8.05(1H, d, J=8.4Hz), 7.82(1H, d, J=7.0Hz), 7.73(1H, dd, J=8.1, 7.0Hz), 7.59-7.49(2H, m), 7.34-7.19(3H, m), 7.16(1H, dd, J=8.7, 8.7Hz), 5.86(2H, s), 5.37(2H, s), 5.21(2H, s), 3.47(3H, s).

IR (KBr) cm<sup>-1</sup> : 1664, 1623, 1600, 1497, 1291, 1266, 1158, 1001, 983, 825, 781, 750.

Example 37 (alternative synthesis method for obtaining the compound of Example 28)

Synthesis of 6-hydroxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one:

[0057] 6-methoxymethoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one (444 mg, 0.85 mmol) was dissolved in a mixture (100 ml) of chloroform-methanol (10:1). A solution (5 ml) of hydrochloric acid (4N) in ethyl acetate was added to the resultant mixture, and the mixture was stirred at room temperature for 17 hours. Water (400 ml) was added thereto, and a saturated aqueous solution of sodium hydrogencarbonate was added dropwise so as to neutralize the aqueous phase, followed by extraction with a mixture of chloroform-methanol (10:1). The organic phase was dried over magnesium sulfate anhydride, and the solvent was removed under reduced pressure. The residue was recrystallized from a chloroform-methanol-diethylether mixture, to thereby obtain the title compound as yellow leaf crystals (353 mg, 0.74 mmol, 87.2%).

mp : 260-267°C (d.)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>-CD<sub>3</sub>OD) δ (ppm) : 8.53(1H, s), 8.35(1H, d, J=8.6Hz), 8.06(1H, d, J=8.3Hz), 7.89(1H, d, J=8.3Hz),

7.78(1H, ddd, J=8.6, 7.1, 1.5Hz), 7.72(1H, d, J=8.6Hz), 7.60(1H, m), 7.33(1H, dd, J=8.8, 8.1Hz), 7.27(1H, d, J=8.8Hz), 7.18(1H, dd, J=8.8, 2.8Hz), 7.15-7.02(4H, m), 5.88(2H, s), 5.39(2H, s).  
IR (KBr)  $\text{cm}^{-1}$  : 1661, 1614, 1508, 1429, 1287, 1229, 1160, 1029, 826, 781.

## 5 Example 38

Synthesis of 6-methoxy-1-methyl-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one:

[0058] To a mixture of 6-methoxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one (1.61 g, 3.30 mmol) and  
10 potassium carbonate (684 mg, 4.95 mmol), was added DMF (30 ml). Methyl iodinate (562 mg, 3.96 mmol) was added  
dropwise to the resultant mixture, and thereafter stirred for four hours at a bath temperature of 80°C. The solvent of the  
reaction mixture was removed under reduced pressure. Water was added to the mixture, and the organic phase was  
extracted therefrom with a mixture of chloroform-methanol (10:1). The organic phase was dried over sodium sulfate  
15 anhydride, subjected to silica gel column chromatography (with chloroform-methanol (50:1)), and concentrated under  
reduced pressure. The resultant residue was recrystallized from a chloroform-n-hexan-ether mixture, to thereby obtain  
the title compound (1.35 g, 2.68 mmol, 81.1%) as pale yellow powder.

mp : 125-127°

<sup>1</sup>H-NMR ( $\text{CDCl}_3$ )  $\delta$  (ppm) : 8.57(1H, s), 8.19(1H, d, J=8.6Hz), 8.07(1H, d, J=8.5Hz), 7.81(1H, d, J=8.3Hz), 7.72(1H,  
20 ddd, J=8.3, 6.8, 1.5Hz), 7.64(1H, d, J=8.6Hz), 7.53(1H, dd, J=8.3, 7.8Hz), 7.36(1H, d, J=9.0Hz), 7.32-7.24(2H, m),  
7.13-7.09(2H, m), 7.04(1H, d, J=7.6Hz), 6.99(1H, dd, J=7.6, 2.2Hz), 5.85(2H, s), 5.36(2H, s), 3.89(3H, s), 3.81(3H,  
s).  
IR (KBr)  $\text{cm}^{-1}$  : 3442, 1664, 1589, 1577, 1442, 1237, 1160, 1066, 1031, 928, 786, 768.

## 25 Examples 39 through 43

[0059] In a manner similar to that of Example 38, the compounds shown in Table 5 below were obtained.

Table 5

Ex.	Compound	m.p.
39	1-Dimethylaminoethyl-6-hydroxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazol}quinolin-2-one	179~181°C (d.)
40	1-Dimethylaminoethyl-6-hydroxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	153~155°C
41	1-Dimethylaminoethyl-6-methoxy-3-{1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	154~158°C
42	1-Dimethylaminopropyl-6-hydroxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one	169~172°C (d.)
43	1-Dimethylaminoethyl-6-hydroxy-3-{2-[3-(2-quinolylethenyl)benzyl]tetrazolyl}quinolin-2-one	148~152°C (d.)

## 45 Example 44

Synthesis of 1-(3-chloropropyl)-6-methoxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one:

[0060] A mixture of 6-methoxy-3-{2-[3-(2-quinolylmethoxy) benzyl]tetrazolyl}quinolin-2-one (1.00 g, 2.04 mmol),  
50 potassium carbonate (564 mg, 4.08 mmol), 1-bromo-3-chloropropane (962 mg, 6.12 mmol), and DMF (100 ml) was  
stirred for four hours at a bath temperature of 60°C. The solvent of the reaction mixture was removed under reduced  
pressure. Water was then added to the mixture, and the mixture was extracted with chloroform-methanol (10:1). The  
thus-obtained organic phase was dried over magnesium sulfate anhydride, and the solvent was removed under  
55 reduced pressure. The organic phase was then subjected to silica gel column chromatography (developer: chloroform-  
methanol (100:1)), purified, and crystallized from a chloroform-diethylether mixture, to thereby obtain the title com-  
pound (546 mg, 0.963 mmol, 47.2%) as pale yellow powder.



mp : 150-152°C

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 8.60(1H, s), 8.18(1H, d, J=8.5Hz), 8.07(1H, d, J=8.3Hz), 7.81(1H, d, J=9.0Hz), 7.72(1H, ddd, J=8.3, 7.8, 1.5Hz), 7.64(1H, d, J=8.3Hz), 7.53(1H, dd, J=8.1, 6.8Hz), 7.46(1H, d, J=9.3Hz), 7.33-7.24(2H, m), 7.15-7.08(2H, m), 7.06-6.96(2H, m), 5.85(2H, s), 5.36(2H, s), 4.53(2H, t, J=7.8Hz), 3.89(3H, s), 3.73(2H, t, J=6.3Hz), 2.29(2H, m).

IR (KBr) cm<sup>-1</sup> : 1660, 1590, 1573, 1508, 1445, 1428, 1267, 1159, 829, 767.

[0061] Further, the by-product was crystallized from a chloroform-diethylether mixture, to thereby obtain 2-chloropropoxy-6-methoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinoline (173 mg, 0.305 mmol, 15.0%) as white powder.

#### Example 45

Synthesis of 1-[3-[4-(2-quinolylmethyl)-1-piperazinyl]propyl]-6-methoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one dihydrochloride:

[0062] A mixture of 1-(3-chloropropyl)-6-methoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one (179 mg, 0.316 mmol) and N-(2-quinolylmethyl)piperazine (287 mg, 1.26 mmol) was stirred under an argon flow at 120°C for 2.5 hours. The mixture was allowed to cool, subjected to silica gel column chromatography (developer: chloroform-methanol (40:1)), and purified. Fractions including the target compound were collected, and concentrated under reduced pressure, to thereby obtain the free base of the title compound (219 mg, 0.289 mmol) as yellow oily matter. The thus-obtained free base of the title compound was dissolved in methanol (50 ml), and a solution of hydrochloric acid (4N) in ethyl acetate (144 μl, 0.576 mmol) was added to the resultant mixture. The mixture was crystallized from a methanol-diethylether mixture, to thereby obtain the title compound (184 mg, 0.22 mmol, 70.1%) as yellow powder.

mp : 182-186°

<sup>1</sup>H-NMR (CDCl<sub>3</sub>-CD<sub>3</sub>OD) δ (ppm) : 8.73(1H, d, J=8.6Hz), 8.66(1H, d, J=8.1Hz), 8.60(1H, s), 8.53(1H, d, J=8.1Hz), 8.05-7.79(6H, m), 7.70(1H, dd, J=7.8, 7.3Hz), 7.59(1H, d, J=9.3Hz), 7.40-7.30(2H, m), 7.22-7.15(2H, m), 7.10-7.04(2H, m), 5.88(2H, s), 5.55(2H, s), 4.53(2H, t, J=6.3Hz), 4.34(2H, s), 3.91(3H, s), 3.54(4H, br), 3.37(2H, m), 3.22(4H, br), 2.37(2H, m).

IR (KBr) cm<sup>-1</sup> : 1652, 1625, 1576, 1509, 1455, 1240, 1028, 772, 475.

#### Examples 46 through 49

[0063] In a manner similar to that of Example 45, the compounds shown in Table 6 below were obtained.

Table 6

Ex.	Compound	m.p.
46	6-Methoxy-1-[3-(4-methylpiperazinyl)propyl]-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	191~195°C (d.)
47	6-Methoxy-1-[4-[4-(2-quinolylmethyl)piperazinyl]butyl]-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one dimalate	179~181°C (d.)
48	6-Methoxy-1-[3-[4-(2-pyridylmethyl)piperazinyl]propyl]-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one dihydrochloride	161~164°C (d.)
49	6-Methoxy-3-[2-[3-(2-quinolylethenyl)benzyl]tetrazolyl]-1-[3-[4-(2-quinolylmethyl)piperazinyl]propyl]quinolin-2-one dimalate	156~158°C (d.)

#### Example 50

Synthesis of 6-dimethylaminoethoxy-1-dimethylaminoethyl-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one dioxalate:

[0064] To a mixture of 6-dimethylaminoethyl-3-1-hydroxy-[2-[3-[2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one (700 mg, 1.28 mmol) and potassium carbonate (706 mg, 5.11 mmol), was added DMF (40 ml), and the resultant mixture was stirred. Dimethylaminoethylchloride (369 mg, 2.56 mmol) was then added to the mixture, and the mixture was

stirred for three days at a bath temperature of 80°C.

[0065] The reaction mixture was concentrated under reduced pressure. After addition of water, the reaction mixture was extracted with a mixture of chloroform-methanol (10:1). The thus-obtained organic phase was dried over sodium sulfate anhydrate, and the solvent was removed under reduced pressure. The organic phase was then subjected to silica gel column chromatography (with chloroform-ammoniasaturated-methanol (10:1)). The solvent of the fractions including the target compound was removed under reduced pressure, to thereby obtain the free base of the title compound (254 mg, 0.411 mmol, 32.1%) as brown oily matter.

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 8.57(1H, s), 8.18(1H, d, J=8.5Hz), 8.06(1H, d, J=8.3Hz), 7.81(1H, d, J=8.1Hz), 7.73(1H, ddd, J=8.5, 6.8, 1.5Hz), 7.64(1H, d, J=8.3Hz), 7.52(1H, dd, J=8.2, 6.8Hz), 7.40(1H, d, J=9.3Hz), 7.34-7.23(2H, m), 7.14(1H, d, J=2.7Hz), 7.10(1H, s), 7.05-6.95(2H, m), 5.86(2H, s), 5.36(2H, s), 4.50(2H, t, J=8.1Hz), 4.13(2H, t, J=5.6Hz), 2.77(2H, t, J=5.6Hz), 2.67(2H, t, J=8.1Hz), 2.40(6H, s), 2.36(6H, s).

[0066] The thus-obtained free base of the title compound was dissolved in methanol, and oxalic acid (148 mg, 0.422 mmol) was added to the resultant mixture. Subsequently, the mixture was recrystallized from an acetone-ether mixture, to thereby obtain the dioxalate (211 mg, 0.270 mmol, 21.1%) of the title compound as brown powder.

mp : 172-176°C (d.)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>) δ (ppm) : 8.52(1H, s), 8.24(1H, d, J=8.1Hz), 8.05(1H, d, J=8.6Hz), 7.84(1H, d, J=7.6Hz), 7.78-7.67(2H, m), 7.66(1H, d, J=8.5Hz), 7.56(1H, ddd, J=9.3, 8.1, 1.2Hz), 7.47-7.38(1H, m), 7.31(1H, dd, J=7.8, 8.1Hz), 7.17(1H, m), 7.12(1H, m), 7.07-7.68(2H, m), 5.85(2H, s), 5.35(2H, s), 4.70(2H, m), 4.40(2H, m), 3.49(2H, m), 3.30(2H, m), 2.95(6H, s), 2.94(6H, s).

IR (KBr) cm<sup>-1</sup> : 3419, 1652, 1599, 1509, 1448, 1312, 1281, 1239, 1161, 1055, 831.

#### Example 51

Synthesis of 6-(3-chloropropyl)oxy-1-methyl-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one:

[0067] To a mixture of 6-hydroxy-1-methyl-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one (600 mg, 1.22 mmol) and potassium carbonate (337 mg, 2.44 mmol), was added DMF (100 ml), and the resultant mixture was stirred. 1-Bromo-3-chloropropane (578 mg, 3.64 mmol) was then added thereto, followed by stirring at a bath temperature of 60°C for four hours. The reaction mixture was concentrated under reduced pressure, and water was added thereto, followed by extraction with a mixture of chloroform-methanol (10:1). The residue was dried over sodium sulfate anhydrate, and the solvent was removed under reduced pressure, to thereby obtain the title compound (638 mg) in a crude form as yellow oily matter.

<sup>1</sup>H-NMR(CDCl<sub>3</sub>) δ (ppm) : 8.52(1H, s), 8.17(1H, d, J=8.6Hz), 8.06(1H, d, J=8.5Hz), 7.80(1H, d, J=8.1Hz), 7.71(1H, ddd, J=8.3, 7.1, 1.5Hz), 7.63(1H, d, J=8.5Hz), 7.51(1H, dd, J=8.1, 6.8Hz), 7.35-7.21(3H, m), 7.14-7.09(2H, m), 7.04(1H, d, J=7.6Hz), 6.98(1H, dd, J=8.3, 2.4Hz), 5.85(2H, s), 5.35(2H, s), 4.17(2H, t, J=5.9Hz), 3.84-3.73(5H, m), 2.27(2H, t, J=6.1Hz).

#### Example 52

Synthesis of 1-methyl-6-[3-(4-methylpiperazinyl)propyl]oxy-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one trihydrochloride:

[0068] A mixture of crude 6-[3-chloropropyl]oxy-1-methyl-3-{2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl}quinolin-2-one (180 mg, 0.317 mmol) and N-methylpiperazine (127 mg, 1.27 mmol) was stirred under an argon flow at a bath temperature of 120°C for 90 minutes. The reaction mixture was concentrated under reduced pressure, and purified through silica gel chromatography (developer: chloroform-methanol (20:1)). Fractions containing the target compound were collected, and concentrated under reduced pressure, to thereby obtain the free base of the title compound (180 mg, 0.285 mmol) as yellow oily matter. The thus-obtained free base was dissolved in methanol (2 ml), and a solution of hydrochloric acid (4N) in ethyl acetate (285 μl, 1.14 mmol) was added thereto. The mixture was crystallized from a methanol-diethylether mixture, to thereby obtain the trihydrochloride; i.e., the title compound, as yellow needles (143 mg, 0.203 mmol, 64.1%).

mp : 188-192°C (d.)

<sup>1</sup>H-NMR (CDCl<sub>3</sub>-CD<sub>3</sub>OD) δ (ppm) : 8.77(1H, d, J=8.6Hz), 8.54(1H, s), 8.46(1H d, J=8.8Hz), 8.11(1H, d, J=8.6Hz),

8.08-7.98(2H, m), 7.82(1H, dd, J=7.6, 7.3Hz), 7.46-7.32(2H, m), 7.30-7.05(5H, m), 5.90(2H, s), 5.69(2H, s), 4.21(2H, overlapped with solvent), 3.90-3.65(11H, m), 3.51(2H, m), 2.98(3H, m), 2.41(2H, br).  
IR (KBr)  $\text{cm}^{-1}$  : 1647, 1623, 1578, 1510, 1456, 1384, 1241, 1162, 1060, 963.

# Example 53

Synthesis of 6-[3-[4-(2-quinolylmethyl) piperazinyl]propyl]oxy-1-methyl-3-(2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one:

[0069] In a manner similar to that of Example 52, the title compound was obtained.

mp : 174-178°C (d.)

$^1\text{H-NMR}$  ( $\text{DMSO-d}_6$ )  $\delta$  (ppm) : 8.62(1H, d, J=8.3Hz), 8.53(1H, s), 8.48(1H, d, J=8.8Hz), 8.21-7.97(4H, m), 7.93-7.71(5H, m), 7.66-7.50(3H, m), 7.41-7.33(2H, m), 7.16-7.07(2H, m), 7.01(1H, d, J=7.8Hz), 6.00(2H, s), 5.42(2H, s), 4.60(2H, br), 4.17(2H, t, J=6.1Hz), 3.80-3.30(8H, overlapped with solvent), 3.69(3H, s), 2.25(2H, br).

IR (KBr)  $\text{cm}^{-1}$  : 1647, 1600, 1578, 1509, 1449, 1430, 1239, 1159.

# Example 54

Synthesis of 6-butyryloxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one:

[0070] 6-Hydroxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one (250 mg, 0.522 mmol) was dissolved in pyridine (30 ml), and butyric anhydride (172  $\mu\text{l}$ , 1.05 mmol) was added thereto, followed by stirring at room temperature for 20 hours. A small amount of methanol was added to the reaction mixture, and the solvent was then removed. The residue was dissolved in a chloroform-methanol (10:1) mixture, followed by sequential washing with hydrochloric acid (2N), water, a saturated aqueous solution of sodium hydrogencarbonate, and water. The organic phase was dried over magnesium sulfate anhydride, and the solvent was removed under reduced pressure. The residue was purified through silica gel chromatography (developer: chloroform-methanol (10:1)), followed by recrystallization with a chloroform-methanol-diethylether mixture, to thereby obtain the title compound as white powder (265 mg, 0.485 mmol, 92.8%).

mp : 200-202°C (d.)

$^1\text{H-NMR}$  ( $\text{CDCl}_3$ )  $\delta$  (ppm) : 11.1(1H, br), 8.64(1H, s), 8.16(1H, d, J=8.8Hz), 8.05(1H, d, J=8.1Hz), 7.79(1H, d, J=8.1Hz), 7.70(1H, ddd, J=8.4, 7.0, 1.5Hz), 7.62(1H, d, J=8.4Hz), 7.51(1H, m), 7.42(1H, d, J=2.2Hz), 7.36-7.27(3H, m), 7.14-6.98(3H, m), 5.87(2H, s), 5.37(2H, s), 2.67(2H, t, J=7.3Hz), 1.80(2H, tq, J=7.3, 7.3Hz), 1.06(3H, t, J=7.3Hz).

IR (KBr)  $\text{cm}^{-1}$  : 1755, 1675, 1586, 1497, 1453, 1226, 1156, 1030, 828, 757.

# Examples 55 through 64

[0071] In a manner similar to that of Example 54, the following compounds were obtained.

Table 7

Ex.	Compound	m.p.
55	6-Butyryloxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	189~191°C (d.)
56	6-Acetoxy-3-[2-[4-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	226~228°C (d.)
57	6-Acetoxy-3-[1-[4-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	235~238°C (d.)
58	6-Acetoxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	222~225°C
59	6-Acetoxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	218~221°C (d.)
60	6-Propionyloxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	216~218°C (d.)
61	6-Propionyloxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	201~203°C (d.)
62	6-Isobutyryloxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinoline-2-one	195~197°C (d.)

Table 7 (continued)

Ex.	Compound	m.p.
63	6-Isobutyryloxy-3-[1-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	196~199°C (d.)
64	6-Glycyloxy-3-[2-[3-(2-quinolylmethoxy)benzyl]tetrazolyl]quinolin-2-one	196~200°C (d.)

## Test Example 1

10 Antihistaminic action and antileukotriene action (*in vitro* test):

[0072] A guinea pig was subjected to ileectomy, and the ileum was cut to lengths of about 2 cm. Each piece of ileum was suspended in a Tyrode's buffer placed in a 20-ml organ bath. Isotonic contraction in response to histamine or leukotriene D<sub>4</sub> was recorded by use of a recording apparatus. The Tyrode's buffer was aerated with a gas mixture (95% O<sub>2</sub> - 5% CO<sub>2</sub>) while the temperature of the buffer was maintained at 29°C. Antihistaminic activity was tested by adding 10<sup>-8</sup> to 10<sup>-4</sup> M histamine to the organ bath and obtaining a dose-response curve. After washing with a buffer several times, a test compound was added to the organ bath. Thirty minutes later, another dose-response curve of histamine was obtained. For the test of antileukotriene activity, there were investigated effects exerted by addition of a 10<sup>-5</sup> M test compound on the contraction induced with 10<sup>-8</sup> M LTD<sub>4</sub>. In Table 8, antihistaminic action is indicated by pA<sub>2</sub> or pD'<sub>2</sub>, whereas antileukotriene action is indicated by IC<sub>50</sub>.

Table 8

Example	Anti-histaminic action	Anti-LTD <sub>4</sub> action IC <sub>50</sub> (M)
1	5.53pD' <sub>2</sub>	9.0 × 10 <sup>-8</sup>
2	5.38pA <sub>2</sub>	2.5 × 10 <sup>-7</sup>
6	7.39pA <sub>2</sub>	1.1 × 10 <sup>-6</sup>
26	5.24pD' <sub>2</sub>	1.79 × 10 <sup>-7</sup>
38	5.52pD' <sub>2</sub>	1.6 × 10 <sup>-7</sup>
39	7.52pA <sub>2</sub>	5.0 × 10 <sup>-7</sup>
40	6.60pA <sub>2</sub>	6.4 × 10 <sup>-7</sup>
41	5.58pD' <sub>2</sub>	5.9 × 10 <sup>-7</sup>
42	7.26pA <sub>2</sub>	8.4 × 10 <sup>-7</sup>
43	6.76pA <sub>2</sub>	3.6 × 10 <sup>-6</sup>
45	7.66pA <sub>2</sub>	6.4 × 10 <sup>-7</sup>
47	7.70pA <sub>2</sub>	2.1 × 10 <sup>-6</sup>
48	6.94pA <sub>2</sub>	5.0 × 10 <sup>-7</sup>
52	6.04pA <sub>2</sub>	1.3 × 10 <sup>-6</sup>

## Test Example 2

H<sub>1</sub> Receptor binding inhibitory test:

[0073] 50 mM phosphate buffer (pH 7.5, 1 ml) containing 0.5 nM [<sup>3</sup>H] mepyramine (activity: 22 Ci/mmol), guinea pig cerebral membrane protein, and a test compound was incubated at 37°C for 30 minutes. Reaction was stopped by addition of ice-cold phosphate buffer, and immediately thereafter, the reaction mixture was filtered by use of a Wattman CF/C filter. The filter was washed twice, each time with 20 ml ice-cold buffer. Radioactivity of the residue was measured by use of a liquid scintillation counter. From the value as obtained when a test compound was not added and values as obtained when the test compound was added at different concentrations, there was determined a dose-response curve representing suppression action of the test compound, from which a 50% inhibitory concentration (IC<sub>50</sub>) was obtained. Based on the IC<sub>50</sub> value and by use of the Cheng-Prusoff equation, a dissociation constant (K<sub>D</sub>) was calculated (Table

9). In a saturation test,  $10^{-4}$  M R(-)-dimetindene was used for the measurement of the amount of non-specific binding. From the saturation test, it was found that a single type of receptor was involved, and the saturation amount of binding (Bmax) was  $278 \pm 24$  fmol/mg protein. Also, the dissociation constant ( $K_D$ ) of [ $^3$ H]mepyramine was  $3.30 \pm 0.26 \times 10^{-9}$  M, and the slope as analyzed in accordance with Hill plots was 1.005. The figures in Table 9 represent dissociation constants  $K_D$  (M) or inhibition (%) at a high concentration (a: 100  $\mu$ M, b: 10  $\mu$ M).

### Test Example 3

#### LTD<sub>4</sub> Receptor binding inhibitory test:

[0074] 10 mM Piperazine N,N'-bis(2-ethane sulfonate) buffer (pH 7.5, 0.3 ml) containing 0.2 nM [ $^3$ H] leukotriene D<sub>4</sub>, guinea pig lung protein, and a test compound was incubated at 22°C for 30 minutes. Reaction was stopped by addition of ice-cold Tris-HCl/NaCl (10 mM/100 mM, pH 7.5) buffer, and immediately thereafter, the reaction mixture was filtered by use of a Wattman CF/C filter. The filter was washed twice, each time with 20 ml ice-cold buffer. Radioactivity of the residue was measured by use of a liquid scintillation counter. In a manner similar to that applied to the case of the H<sub>1</sub> receptor, IC<sub>50</sub> and the dissociation constant ( $K_D$ ) of the test compound were obtained (see Table 9). In a saturation test, 2  $\mu$ M leukotriene D<sub>4</sub> was used for the measurement of the amount of non-specific binding. From the saturation test, it was found that there was involved a single type of receptor, and the saturation amount of binding (Bmax) was 988 fmol/mg protein. Also, the dissociation constant ( $K_D$ ) of [ $^3$ H]leukotriene D<sub>4</sub> was  $2.16 \times 10^{-10}$  M, and the slope as analyzed in accordance with Hill plots was 0.99.


Table 9

Example	H <sub>1</sub> Receptor $K_D$ (M)	LTD <sub>4</sub> Receptor $K_D$ (M)
1	$2.96 \times 10^{-6}$	$1.14 \times 10^{-7}$
6	$3.29 \times 10^{-6}$	$8.11 \times 10^{-6}$
8	$9.38 \times 10^{-6}$	$1.43 \times 10^{-7}$
9	$1.37 \times 10^{-5}$	$3.20 \times 10^{-7}$
18	$2.28 \times 10^{-5}$	$5.09 \times 10^{-7}$
22	$3.01 \times 10^{-5}$	$3.64 \times 10^{-7}$
24	$9.51 \times 10^{-6}$	$2.05 \times 10^{-7}$
25	$1.39 \times 10^{-5}$	$5.86 \times 10^{-9}$
26	$8.95 \times 10^{-5}$	$1.79 \times 10^{-7}$
28	$1.39 \times 10^{-5}$	$2.10 \times 10^{-8}$
29	$5.72 \times 10^{-5}$	$1.36 \times 10^{-8}$
56	$8.47 \times 10^{-5}$	$3.36 \times 10^{-7}$
58	$4.80 \times 10^{-4}$	$3.82 \times 10^{-8}$
64	$6.19 \times 10^{-5}$	$2.21 \times 10^{-8}$

[0075] As described above, the tetrazole derivative or a salt thereof according to the present invention is endowed with excellent antileukotriene activity and anti-histaminic activity and thus is useful as a medicine for the prevention and treatment of asthma.

### Claims

1. A tetrazole derivative or a salt thereof represented by the following formula (1):



15 wherein R<sup>1</sup> and R<sup>2</sup> independently represent a hydrogen atom, a hydroxyl group, a lower alkyl group, a substituted or unsubstituted alkoxy group, or a substituted or unsubstituted alkanoyloxy group; R<sup>3</sup> represents a hydrogen atom or a substituted or unsubstituted lower alkyl group; A represents a methyleneoxy group or a vinylene group; B represents a substituted or unsubstituted quinolyl group, a substituted or unsubstituted quinazolyl group, or a substituted or unsubstituted benzimidazolyl group; and a broken line indicates that there may be a double bond.

2. A medicine comprising as an active ingredient a tetrazole derivative as described in Claim 1 or a salt thereof.
  - 20 3. The medicine according to Claim 2, which is a preventive or therapeutic drug for an allergic disease.
  4. The medicine according to Claim 2, which is a preventive or therapeutic drug for a disease selected from the group consisting of asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, psoriasis, rheumatism, inflammatory colitis, cerebral ischemia, and cerebral apoplexy.
  - 25 5. A pharmaceutical composition comprising a tetrazole derivative as described in Claim 1 or a salt thereof, and a pharmacologically acceptable carrier.
  6. Use, as a medicine, of a tetrazole derivative as described in Claim 1 or a salt thereof.
  - 30 7. A method for the treatment of an allergic disease, which method comprises administering to a patient in need thereof an effective amount of a tetrazole derivative as described in Claim 1 or a salt thereof.
  - 35 8. A method for the treatment of a disease selected from the group consisting of asthma, allergic rhinitis, allergic conjunctivitis, atopic dermatitis, urticaria, psoriasis, rheumatism, inflammatory colitis, cerebral ischemia, and cerebral apoplexy, which method comprises administering to a patient in need thereof an effective amount of a tetrazole derivative as described in Claim 1 or a salt thereof.
- 40
- 45
- 50
- 55



European Patent  
Office

# PARTIAL EUROPEAN SEARCH REPORT

Application Number

which under Rule 45 of the European Patent Convention shall be considered, for the purposes of subsequent proceedings, as the European search report

EP 98 11 8064

DOCUMENTS CONSIDERED TO BE RELEVANT			
Category	Citation of document with indication, where appropriate, of relevant passages	Relevant to claim	CLASSIFICATION OF THE APPLICATION (Int.Cl.6)
A	EP 0 658 554 A (ELI LILLY AND COMPANY) 21 June 1995 * page 1, line 9 - line 10; claim 1 *	1-5	C07D401/04 A61K31/47 C07D401/14
A	WO 89 05294 A (LEO PHARMACEUTICAL PRODUCTS LTD.) 15 June 1989 * page 8; claim 1 *	1-5	
			TECHNICAL FIELDS SEARCHED (Int.Cl.6)
			C07D A61K
INCOMPLETE SEARCH			
<p>The Search Division considers that the present application, or one or more of its claims, does/do not comply with the EPC to such an extent that a meaningful search into the state of the art cannot be carried out, or can only be carried out partially, for these claims.</p> <p>Claims searched completely :</p> <p>Claims searched incompletely :</p> <p>Claims not searched :</p> <p>Reason for the limitation of the search:</p> <p>Although claims 7 and 8 are directed to a method of treatment of the human/animal body (Article 52(4) EPC), the search has been carried out and based on the alleged effects of the compound/composition.</p>			
Place of search		Date of completion of the search	Examiner
THE HAGUE		30 November 1998	Van Bijlen, H
CATEGORY OF CITED DOCUMENTS			
<p>X : particularly relevant if taken alone</p> <p>Y : particularly relevant if combined with another document of the same category</p> <p>A : technological background</p> <p>O : non-written disclosure</p> <p>P : intermediate document</p> <p>T : theory or principle underlying the invention</p> <p>E : earlier patent document, but published on, or after the filing date</p> <p>D : document cited in the application</p> <p>L : document cited for other reasons</p> <p>&amp; : member of the same patent family, corresponding document</p>			

EPO FORM 1503 03.92 (P04007)

# ANNEX TO THE EUROPEAN SEARCH REPORT ON EUROPEAN PATENT APPLICATION NO.

EP 98 11 8064

This annex lists the patent family members relating to the patent documents cited in the above-mentioned European search report. The members are as contained in the European Patent Office EDP file on The European Patent Office is in no way liable for these particulars which are merely given for the purpose of information.

30-11-1998

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP 658554 A	21-06-1995	US 5486612 A	23-01-1996
		CA 2137642 A	15-06-1995
		JP 7215967 A	15-08-1995
		US 5569764 A	29-10-1996
		US 5622969 A	22-04-1997
WO 8905294 A	15-06-1989	AT 110364 T	15-09-1994
		AU 2611888 A	05-07-1989
		CA 1336602 A	08-08-1995
		DE 3851232 D	29-09-1994
		DE 3851232 T	02-02-1995
		DK 118390 A	14-05-1990
		EP 0420844 A	10-04-1991
		GR 1000422 B	30-06-1992
		IE 64473 B	09-08-1995
		JP 3501477 T	04-04-1991
		PT 89118 A,B	01-12-1988
		US 5110819 A	05-05-1992

EPO FORM P045

For more details about this annex : see Official Journal of the European Patent Office, No. 12/82